Navigation Links
Cancer drug effectiveness substantially advanced
Date:4/8/2010

Santa Barbara, Calif., April 8, 2010 Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug. In a transformative paper published today in the online edition of the journal Science, Erkki Ruoslahti, M.D., Ph.D., distinguished professor at Sanford-Burnham Medical Research Institute and founding member of the UC Santa Barbara-Sanford|Burnham Center for Nanomedicine, Kazuki N. Sugahara, M.D., Ph.D., Tambet Teesalu, Ph.D., and fellow researchers at the Center for Nanomedicine and the Cancer Center of Santa Barbara, announced this significant advance in cancer therapy.

"Drugs generally have difficulty penetrating tumors beyond a few cell diameters from a blood vessel," said Dr. Ruoslahti. "This leaves some tumor cells with a suboptimal dose, increasing the risk of both recurrence and drug resistance. The iRGD peptide solves this problem by activating a transport system in tumors that distributes co-injected drugs into the entire tumor and increases drug accumulation in the tumor."

Dr. Ruoslahti showed in the 1980s that a 3 amino-acid peptide motif (RGDArginine-Glycine-Aspartic Acid) serves as a highly selective identifier of malignant tissue, binding to unique re-ceptors in the vasculature of cancers. The RGD peptide's ability to home to tumors has been used to design new compounds for cancer diagnosis and treatment.

The new variant of RGD (iRGDinternalizing RGD) combines the RGD motif with a tissue penetration element called CendR. Like the earlier RGD peptides, iRGD homes to tumors, but exposure of the CendR motif when the iRGD is enzymatically cleaved activates a transport system through tumor blood vessel walls into the tum
'/>"/>

Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Disparities persist in outcomes for African-American women with advanced breast cancer
2. The immune systems guard against cancer
3. Chip checks for oral cancer
4. New discovery is a significant boost to cancer research
5. VARI study could improve treatments for prostate cancer
6. New cancer therapy may fight cardiovascular disease
7. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
8. Advances reported in quest for drugs targeting childhood cancer
9. Development of new anti-cancer gene therapy approach using lentiviral vectors
10. Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients
11. New way discovered to predict which breast cancer patients should be treated with anthracyclines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... ORLEANS, LA (2 November 2014)—In support of a bold ... Bill & Melinda Gates Foundation today announced an award ... Malaria Vaccine Initiative (MVI) in building new vaccines that ... help realize the "accelerating to zero" agenda. Such vaccines ... what could be called an "immunological bed net." ...
(Date:11/2/2014)... bar and bump into a biologist . . . , ... nerd sketch, researchers have taken this premise and applied it ... meaning in the rising oceans of genomic data. , In ... genome-wide studies are publishing at a dizzying rate. The challenge ... from the noise (and there is no shortage of noise). ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... spit out the bad. A new study from the Monell ... gatekeeper. The research shows that strong bitter taste in and ... of nausea and display a pattern of stomach activity characteristic ... of quality of life for many people, including pregnant women, ...
... booms, the science of making music, the impact of noise ... just some of the intriguing topics that will be presented ... (ASA). The meeting will take place May 23-27, ... The ASA offers complimentary press registration to bona fide working ...
... you don,t swallow it at allis enough to cause that ... according to a new study reported in the April 12th ... work shows that our body and our physiology anticipate the ... contain toxins or anti-nutrients," said Paul Breslin of the Monell ...
Cached Biology News:The nauseating taste of bitter 2The science of sound 2The science of sound 3The science of sound 4The science of sound 5The science of sound 6Bitterness induces nausea, swallowing not required 2
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... periods ended September 30, 2014.  Biorem,s complete 2014 third quarter financial ... Financial Summary:Three-months ended September 30, , Nine-months ... data) , 2014 , 2013 , ... , 5,281 , 6,715 , 14,476 ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... 17, 2014 pH measurement and control ... the pharmaceutical, chemical, and food and beverage industries. But ... and how do pH sensors work? METTLER TOLEDO has ... in process industries with these questions and more. , ... in the process industries. The actual sensor, the pH ...
(Date:11/18/2014)... 18, 2014 Alanda Software, a ... Reporting solutions, announced today that a top tier ... Consummate Provider™ solution in both the U.S. and ... SaaS based, Data Quality remediation portal, designed to ... party Providers improve their ability to capture, transmit ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... -- China-Biotics,Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," "the ... research, development,marketing and distribution of probiotics products, today ... plant at Qing Pu, Shanghai., "The new ... the cornerstone of our,growth strategy. We have put ...
... drive solid ... earnings growth., ST. DAVID,S, Bermuda, May ... for the quarter ended,March 31, 2008. Revenue in the quarter ended March ... quarter. The primary,drivers of the increase in revenue were the net sales ...
... ... AI programs - ... TSX symbol: SBS, CALGARY, May 9 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), ... announced its,2008 first quarter operational and financial results., Highlights, - ...
Cached Biology Technology:China-Biotics, Inc. Completes Foundation for Its New Plant 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 3Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 4Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 5Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 6Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 7Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 8Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 9Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 10Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 11Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 12Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 13Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 14Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 15Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 16Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 17SemBioSys announces first quarter 2008 financial and operational results 2SemBioSys announces first quarter 2008 financial and operational results 3SemBioSys announces first quarter 2008 financial and operational results 4SemBioSys announces first quarter 2008 financial and operational results 5SemBioSys announces first quarter 2008 financial and operational results 6SemBioSys announces first quarter 2008 financial and operational results 7SemBioSys announces first quarter 2008 financial and operational results 8SemBioSys announces first quarter 2008 financial and operational results 9SemBioSys announces first quarter 2008 financial and operational results 10SemBioSys announces first quarter 2008 financial and operational results 11SemBioSys announces first quarter 2008 financial and operational results 12
...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Donor Goat Serum...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: